Drugs / 4SCAR19/22 T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03098355 | Dec 2017 → Dec 2022 | B-cell acute lymphoblastic leukemia | Zhujiang Hospital | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR19/22 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03098355 ↗ |
| Modality | Cell therapy | “autologous T cells are genetically modified with 4th generation anti-CD19 and anti-CD22 CARs (4SCAR19/22) using lentiviral vectors” NCT03098355 ↗ |